Genomma Lab Internacional S.A.B. de C.V Total Liabilities
Genomma Lab Internacional S.A.B. de C.V total liabilities. Based on the latest financial reports, Genomma Lab Internacional S.A.B. de C.V (LABB) has total liabilities worth MX$13.09 Billion MXN (≈ $753.06 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Genomma Lab Internacional S.A.B. de C.V to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Genomma Lab Internacional S.A.B. de C.V (2005–2025)
Total liabilities of Genomma Lab Internacional S.A.B. de C.V from 2005 to 2025. This chart illustrates how Genomma Lab Internacional S.A.B. de C.V's total liabilities have evolved over time, based on quarterly financial data. Explore LABB long-term investment intensity to see how much of total assets are deployed in long-term investments.
Genomma Lab Internacional S.A.B. de C.V Competitors by Total Liabilities
The table below lists competitors of Genomma Lab Internacional S.A.B. de C.V ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Equital
TA:EQTL
|
Israel | ILA12.89 Billion |
|
FAWER Automotive Parts Ltd Co
SHE:000030
|
China | CN¥8.81 Billion |
|
ASGN Inc
NYSE:ASGN
|
USA | $1.88 Billion |
|
Pharming Group NV
AS:PHARM
|
Netherlands | €209.14 Million |
|
BlackRock Credit Allocation Income Trust
NYSE:BTZ
|
USA | $711.43 Million |
|
Orient International Enterprise Ltd
SHG:600278
|
China | CN¥11.22 Billion |
|
Baota Industry Co Ltd
SHE:000595
|
China | CN¥9.27 Billion |
|
VIA Technologies Inc
TW:2388
|
Taiwan | NT$15.11 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Genomma Lab Internacional S.A.B. de C.V's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Genomma Lab Internacional S.A.B. de C.V.
Liquidity & Leverage Metrics
Genomma Lab Internacional S.A.B. de C.V Total Liabilities Ratios Explained
Genomma Lab Internacional S.A.B. de C.V total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genomma Lab Internacional S.A.B. de C.V's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genomma Lab Internacional S.A.B. de C.V (2005–2025)
The table below shows the annual total liabilities of Genomma Lab Internacional S.A.B. de C.V from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | MX$12.72 Billion ≈ $732.22 Million |
+1.83% |
| 2024-12-31 | MX$12.49 Billion ≈ $719.03 Million |
+10.43% |
| 2023-12-31 | MX$11.31 Billion ≈ $651.12 Million |
-1.22% |
| 2022-12-31 | MX$11.45 Billion ≈ $659.18 Million |
-0.15% |
| 2021-12-31 | MX$11.47 Billion ≈ $660.14 Million |
-8.22% |
| 2020-12-31 | MX$12.50 Billion ≈ $719.29 Million |
+10.80% |
| 2019-12-31 | MX$11.28 Billion ≈ $649.20 Million |
+5.93% |
| 2018-12-31 | MX$10.65 Billion ≈ $612.88 Million |
+20.51% |
| 2017-12-31 | MX$8.84 Billion ≈ $508.57 Million |
-0.88% |
| 2016-12-31 | MX$8.92 Billion ≈ $513.10 Million |
+6.34% |
| 2015-12-31 | MX$8.38 Billion ≈ $482.53 Million |
-43.82% |
| 2014-12-31 | MX$14.93 Billion ≈ $858.95 Million |
+75.23% |
| 2013-12-31 | MX$8.52 Billion ≈ $490.18 Million |
+42.58% |
| 2012-12-31 | MX$5.97 Billion ≈ $343.79 Million |
+64.97% |
| 2011-12-31 | MX$3.62 Billion ≈ $208.39 Million |
+110.62% |
| 2010-12-31 | MX$1.72 Billion ≈ $98.94 Million |
+44.37% |
| 2009-12-31 | MX$1.19 Billion ≈ $68.54 Million |
+125.64% |
| 2008-12-31 | MX$527.79 Million ≈ $30.37 Million |
-12.99% |
| 2007-12-31 | MX$606.59 Million ≈ $34.91 Million |
+56.12% |
| 2006-12-31 | MX$388.54 Million ≈ $22.36 Million |
+25.03% |
| 2005-12-31 | MX$310.77 Million ≈ $17.88 Million |
-- |
About Genomma Lab Internacional S.A.B. de C.V
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Mexico and internationally. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products t… Read more